Articles

ASCB Show Preview: A new universality in cell biology

Engineering, physics, computational modeling and quantitative methods are all part of this year’s ASCB special sessions
Written byLloyd Dunlap
| 14 min read

American Society for Cell Biology (ASCB)

54th Annual Meeting

Pennsylvania Convention Center

Philadelphia

Dec. 6-10, 2014

PHILADELPHIA—It is not by chance that the American Society for Cell Biology’s 54th ASCB Annual Meeting is co-hosted this year by the International Federation of Cell Biology (IFCB). Indeed not.

“You are a cell biologist, whether you think of yourself that way or not,” notes Wallace Marshall, chair of the Program Committee for the 2014 ASCB Annual Meeting. “Regardless of what field is stamped on your union card, if you care about cell biology, you need to go to the ASCB Annual Meeting, which this year is being held jointly with the International Federation for Cell Biology.”

Cell biology and disease

The field of cell biology is constantly evolving, Marshall notes, “and an important goal of the annual meeting is to track new developments. In recent years, there has been a growing appreciation of the role of cellular dysfunction in diseases. Studies at the interface of medicine and cell biology have shed important light on both fields, and so for the past several years the ASCB Annual Meeting has devoted special attention to highlighting the cell biological basis of disease and medicine.”

“At this year’s ASCB/IFCB meeting, we will continue this trend in two ways,” Marshall observes. “First, we will have a special bench-to-bedside panel discussion on translation of cell biological discoveries to the understanding and treatment of disease. Second, we have included disease experts as organizers of many of the sessions, and these experts will help stimulate thinking about disease connections across the full spectrum of cell biological topics.”

“Another emerging trend in cell biology is the constantly increasing importance of quantitative concepts and approaches,” he adds. “The living cell is an emergent phenomenon, produced by the mutual interaction of huge numbers of molecules. The only way to begin to understand how such a complex system assembles and functions is to harness the same tools and conceptual approaches that have proven useful in engineering and physics.”

In recent years, Marshall notes, the importance of computational modeling and quantitative methods has been emphasized in special sessions, such as ones on mathematical modeling.

“But having one or two special sessions on quantitative thinking also creates a sense that this is a different way of approaching cell biology, perhaps as a supplement to ‘real’ cell biology,” he says. “Indeed, I attended one session on the role of modeling in which it was implied that models are something to be added onto the end of a cell biology paper to increase publishability, much as a piece of parsley may be added as a garnish to a steak dinner. In my humble opinion, this approach is completely backwards and misses the most important value of a model, that it can be used to help design the experiments from the outset of a project.

“So this year, rather than isolating modeling and quantification in their own separate compartment, like toxic enzymes to be sequestered in the lysosome, we decided to let quantitative and physical sciences pervade the entire meeting by appointing quantitative cell biologists to co-chair many of the minisymposium sessions.”

Marshall explains that to balance the tasks of increasing coverage of disease and quantitative biology, while retaining the traditional core topics of cell biology, they assembled a tripartite Program Committee, consisting of a “core” subcommittee (Mohan Balasubramanian, Magdalena Bezanilla, Orna Cohen-Fix, Ana Maria Cuervo, Beatriz Fontoura, Cynthia Jensen, Franck Perez, William Prinz, Lois Weisman, Mark Winey, Richard Youle and Xiaodong Wang); a “cell biology and disease” subcommittee (Helen Blau, Catherine Dulac, Tom Misteli, Gregory Pazour, Jody Rosenblatt and Marino Zerial); and a “physical and quantitative cell biology” subcommittee (Marileen Dogterom, Aki Kusumi, David Odde and Jitu Mayor).

“Keeping all the conference calls between these groups organized was only possible through the tireless efforts of ASCB’s Meeting and Abstracts Manager Alison Harris,” he adds. “Three other participants deserve special mention. ASCB President Jennifer Lippincott-Schwartz and Executive Director Stefano Bertuzzi never failed to offer their own insights and perspectives, which we found invaluable as we grappled with difficult decisions about topics and organization. In addition, Cynthia Jensen of the IFCB has been one of the most active participants in all of our conference calls and has played an invaluable role in helping to organize this joint meeting.”

Four reasons to attend ASCB 2014

“First of all,” the ASCB’s program chair emphasizes, “you need to go to the meeting because it is simply the most efficient way to learn about the latest thinking, methods and results in the field. Whether you are an established investigator or someone just starting out, you need to have access to this cutting-edge information.”

To continue reading this article, subscribe for FREE toDrug Discovery News Logo

Subscribe today to keep up to date with the latest advancements and discoveries in drug development achieved by scientists in pharma, biotech, non-profit, academic, clinical, and government labs.

Add Drug Discovery News as a preferred source on Google

Add Drug Discovery News as a preferred Google source to see more of our trusted coverage.

About the Author

Here are some related topics that may interest you:

Published In

Subscribe to Newsletter

Subscribe to our eNewsletters

Stay connected with all of the latest from Drug Discovery News.

Subscribe

Sponsored

A 3D rendering illustrates a sandwich ELISA technique, where antigen detection is achieved between two layers of antibodies: a capture antibody and a detection antibody
Learn the key characteristics that determine whether an immunoassay generates accurate and reproducible data.
Illustration of translucent Y-shaped antibodies floating in a soft blue and green background, representing antibody research, development, and biomedical science.
Explore how antibody accessibility and custom development strategies can influence the pace and success of translational research.
Digital illustration of a glowing DNA double helix surrounded by interconnected circuit-like lines on a dark blue background.
Learn the key differences between chemical and enzymatic approaches to synthetic DNA production and their implications for modern research.
Drug Discovery News December 2025 Issue
Latest IssueVolume 21 • Issue 4 • December 2025

December 2025

December 2025 Issue

Explore this issue